Efficacy and safety of fosravuconazole L‐lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double‐blind, randomized phase III study

Fosravuconazole L‐lysine ethanolate (F‐RVCZ) is a prodrug of ravuconazole, a novel triazole antifungal agent, exerting broad and potent antifungal activity. The efficacy and safety of F‐RVCZ, compared with a placebo, were investigated in a multicenter, double‐blind, randomized study of Japanese onyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Shinichi, Tsubouchi, Ichiro, Okubo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220848/
https://www.ncbi.nlm.nih.gov/pubmed/30156314
http://dx.doi.org/10.1111/1346-8138.14607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220848/
https://www.ncbi.nlm.nih.gov/pubmed/30156314
http://dx.doi.org/10.1111/1346-8138.14607

Ejemplares similares